株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

免疫血液学:医療機器のパイプライン評価

Immunohematology - Medical Devices Pipeline Assessment, 2019

発行 GlobalData 商品コード 666937
出版日 ページ情報 英文 101 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.31円で換算しております。
免疫血液学:医療機器のパイプライン評価 Immunohematology - Medical Devices Pipeline Assessment, 2019
出版日: 2019年11月14日 ページ情報: 英文 101 Pages
概要

当レポートでは、世界の免疫血液学の関連市場における、主要なパイプライン製品とその治験の進行状況について調査すると共に、製品の機能・特性の比較分析 (治験の進行段階別) や、主要企業・組織のプロファイルおよび代表的製品、昨今の市場動静 (業績報告・資本取引動向など) といった情報を取りまとめてお届けいたします。

第1章 目次

第2章 イントロダクション

  • 免疫血液学の概要

第3章 治験中の製品

  • パイプライン製品:治験段階別
  • パイプライン製品:分野別
  • パイプライン製品:地域別
  • パイプライン製品:規制経路別
  • パイプライン製品:推定認証時期別

第4章 免疫血液学:治験中のパイプライン製品、企業別

  • 免疫血液学の企業:治験段階別のパイプライン製品
  • 免疫血液学:治験段階別のパイプライン製品

第5章 免疫血液学市場:企業・製品の概要

  • AbSorber AB
  • Amity University
  • Arizona State University
  • Biofortuna Ltd
  • Grifols SA
  • Haemonetics Corp
  • Immucor, Inc.
  • Ortho-Clinical Diagnostics Inc
  • Quotient Limited
  • TBG Diagnostics Ltd
  • Transfusion & Transplantation Technologies (Inactive)

第6章 免疫血液学市場:昨今の動向

第7章 付録

図表

List of Tables

  • Table 1: Immunohematology - Pipeline Products by Stage of Development 8
  • Table 2: Immunohematology - Pipeline Products by Segment 9
  • Table 3: Immunohematology - Pipeline Products by Territory 10
  • Table 4: Immunohematology - Pipeline Products by Regulatory Path 11
  • Table 5: Immunohematology - Pipeline Products by Estimated Approval Date 12
  • Table 6: Immunohematology Companies - Pipeline Products by Stage of Development 13
  • Table 7: Immunohematology - Pipeline Products by Stage of Development 14
  • Table 8: AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview 15
  • Table 9: ABO Diagnostic Test - Product Status 15
  • Table 10: ABO Diagnostic Test - Product Description 15
  • Table 11: Alba Bioscience Limited Pipeline Products & Ongoing Clinical Trials Overview 16
  • Table 12: ALBAcyte O Adult i Cell Reagent - Product Status 16
  • Table 13: ALBAcyte O Adult i Cell Reagent - Product Description 16
  • Table 14: ALBAcyte O RhD VI Reagent Cells - Product Status 16
  • Table 15: ALBAcyte O RhD VI Reagent Cells - Product Description 17
  • Table 16: Amity University Pipeline Products & Ongoing Clinical Trials Overview 18
  • Table 17: Blood Group Testing Kit - Product Status 18
  • Table 18: Blood Group Testing Kit - Product Description 18
  • Table 19: Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 19
  • Table 20: Blood Screening Immunosignaturing - Product Status 19
  • Table 21: Blood Screening Immunosignaturing - Product Description 19
  • Table 22: Biofortuna Ltd Pipeline Products & Ongoing Clinical Trials Overview 20
  • Table 23: HemoPlex Kell Genotyping Kit - Product Status 20
  • Table 24: HemoPlex Kell Genotyping Kit - Product Description 20
  • Table 25: HemoPlex Kidd & Duffy Genotyping Kit - Product Status 21
  • Table 26: HemoPlex Kidd & Duffy Genotyping Kit - Product Description 21
  • Table 27: HemoPlex MNS Genotyping Kit - Product Status 21
  • Table 28: HemoPlex MNS Genotyping Kit - Product Description 21
  • Table 29: HemoPlex Multi Blood Group Genotyping Kit - Product Status 22
  • Table 30: HemoPlex Multi Blood Group Genotyping Kit - Product Description 22
  • Table 31: HemoPlex RHCE Screening Kit - Product Status 22
  • Table 32: HemoPlex RHCE Screening Kit - Product Description 22
  • Table 33: HemoPlex RHCE Variant Genotyping Kit - Product Status 23
  • Table 34: HemoPlex RHCE Variant Genotyping Kit - Product Description 23
  • Table 35: HemoPlex RHD & CE Genotyping Kit - Product Status 23
  • Table 36: HemoPlex RHD & CE Genotyping Kit - Product Description 23
  • Table 37: HemoPlex RHD Variant Genotyping Kit - Product Status 24
  • Table 38: HemoPlex RHD Variant Genotyping Kit - Product Description 24
  • Table 39: ThromboPlex HPA Screening Kit - Product Status 24
  • Table 40: ThromboPlex HPA Screening Kit - Product Description 25
  • Table 41: Grifols SA Pipeline Products & Ongoing Clinical Trials Overview 26
  • Table 42: IH Blood Genotyping (D) Kit - Product Status 26
  • Table 43: IH Blood Genotyping (D) Kit - Product Description 26
  • Table 44: Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 27
  • Table 45: ORTHO AutoVue - Rare Sera Assay - Product Status 27
  • Table 46: ORTHO AutoVue - Rare Sera Assay - Product Description 27
  • Table 47: ORTHO BioVue - Rare Sera Assay - Product Status 28
  • Table 48: ORTHO BioVue - Rare Sera Assay - Product Description 28
  • Table 49: Quotient Ltd Pipeline Products & Ongoing Clinical Trials Overview 29
  • Table 50: Eluate Kit - Product Status 29
  • Table 51: Eluate Kit - Product Description 29
  • Table 52: Expanded IH Microarray - Product Status 30
  • Table 53: Expanded IH Microarray - Product Description 30
  • Table 54: IH Microarray Patient - Product Status 30
  • Table 55: IH Microarray Patient - Product Description 30
  • Table 56: Polyagglutionation Kit - Product Status 31
  • Table 57: Polyagglutionation Kit - Product Description 31
  • Table 58: Sensitivity Kit Anti-S, K, e, C - Product Status 31
  • Table 59: Sensitivity Kit Anti-S, K, e, C - Product Description 31
  • Table 60: Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 33

List of Figures

  • Figure 1: Immunohematology - Pipeline Products by Stage of Development 7
  • Figure 2: Immunohematology - Pipeline Products by Segment 8
  • Figure 3: Immunohematology - Pipeline Products by Territory 9
  • Figure 4: Immunohematology - Pipeline Products by Regulatory Path 10
  • Figure 5: Immunohematology - Pipeline Products by Estimated Approval Date 11
目次
Product Code: GDME0816EPD

GlobalData's Medical Devices sector report, "Immunohematology - Medical Devices Pipeline Assessment, 2019" provides an overview of Immunohematology currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Immunohematology pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Immunohematology under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Immunohematology and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Immunohematology under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

  • 1.1 List of Tables 4
  • 1.2 List of Figures 5

2 Introduction 6

  • 2.1 Immunohematology Overview 6

3 Products under Development 7

  • 3.1 Immunohematology - Pipeline Products by Stage of Development 7
  • 3.2 Immunohematology - Pipeline Products by Segment 8
  • 3.3 Immunohematology - Pipeline Products by Territory 9
  • 3.4 Immunohematology - Pipeline Products by Regulatory Path 10
  • 3.5 Immunohematology - Pipeline Products by Estimated Approval Date 11

4 Immunohematology - Pipeline Products under Development by Companies 12

  • 4.1 Immunohematology Companies - Pipeline Products by Stage of Development 12
  • 4.2 Immunohematology - Pipeline Products by Stage of Development 13

5 Immunohematology Companies and Product Overview 14

  • 5.1 AbSorber AB Company Overview 14
    • 5.1.1 AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview 14
  • 5.2 Alba Bioscience Limited Company Overview 15
    • 5.2.1 Alba Bioscience Limited Pipeline Products & Ongoing Clinical Trials Overview 15
  • 5.3 Amity University Company Overview 17
    • 5.3.1 Amity University Pipeline Products & Ongoing Clinical Trials Overview 17
  • 5.4 Arizona State University Company Overview 18
    • 5.4.1 Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 18
  • 5.5 Biofortuna Ltd Company Overview 19
    • 5.5.1 Biofortuna Ltd Pipeline Products & Ongoing Clinical Trials Overview 19
  • 5.6 Grifols SA Company Overview 24
    • 5.6.1 Grifols SA Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.7 Ortho-Clinical Diagnostics Inc Company Overview 25
    • 5.7.1 Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.8 Quotient Ltd Company Overview 27
    • 5.8.1 Quotient Ltd Pipeline Products & Ongoing Clinical Trials Overview 27
  • 5.9 Transfusion & Transplantation Technologies (Inactive) Company Overview 30
    • 5.9.1 Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 30

6 Immunohematology- Recent Developments 35

  • 6.1 Nov 04, 2019: Quotient reports second quarter fiscal 2020 financial results 35
  • 6.2 Nov 01, 2019: Haemonetics reports 2nd quarter and 1st half fiscal 2020 results; raises fiscal 2020 adjusted operating margin and adjusted EPS guidance 37
  • 6.3 Oct 31, 2019: Bio-Rad reports third-quarter 2019 financial results 39
  • 6.4 Oct 31, 2019: Bio-Rad reports third-quarter 2019 financial results. 40
  • 6.5 Oct 14, 2019: Biocare Medical appoints Nicolas Barthelemy as Executive Chairman 41
  • 6.6 Sep 24, 2019: Theradiag announces improved results for H1 2019 41
  • 6.7 Sep 12, 2019: Haemonetics Appoints Stewart W. Strong As President, Global Hospital 44
  • 6.8 Sep 11, 2019: Bio-Rad files new lawsuit against 10X Genomics for Patent Infringement 45
  • 6.9 Aug 29, 2019: Siemens Healthineers announces new Canadian leadership 45
  • 6.10 Aug 06, 2019: Haemonetics reports 1st Quarter Fiscal 2020 results, updates Fiscal 2020 earnings guidance and launches operational excellence program 46

7 Appendix 98

  • 7.1 Methodology 98
  • 7.2 About GlobalData 101
  • 7.3 Contact Us 101
  • 7.4 Disclaimer 101